Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
£177.00 - £410.00
Next Earnings Date
May 07 2025
Next Earnings Date
May 07 2025
Last Price
Market Cap | £228.57M |
EV | £119.58M |
Shares Outstanding | 106.31M |
Beta | 1.21 |
Analyst Rating | BUY |
Analyst Target Price | £6.49 |
P/E 2025E | - |
P/Revenue 2025E | 7.40x |
Revenue | 4.50% |
EPS | -22.90% |
Operating Cash Flow | -37.30% |
Free Cash Flow | -26.30% |
Revenue | 17.50% |
EPS | 7.40% |
Operating Cash Flow | - |
Free Cash Flow | 21.30% |
Gross Margin 2025E | 84.83% |
Net Profit Margin 2025E | -93.12% |
ROE 2025E | -19.15% |
ROCE 2024 | -18.73% |
DPS 2025E | £0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
MaxCyte, Inc.
MXCT
Sector
Healthcare
Industry
Medical - Devices
CEO
Masoud, Maher
Employees
114
Website
www.maxcyte.comIPO Date
2016-03-29
Headquarters
9713 Key West Avenue, Suite 400, Rockville, Maryland, 20850, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved